The majority of targeted cancer therapies in use today or in clinical studies are inhibitors of proteins that increase cancer cell proliferation as exemplified by epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) or ERBB2 inhibitors in breast cancer. Here, ERBB2 is linked to non-small cell lung carcinoma.